top of page

ASH 2024: BeiGene CEO John Oyler on degraders, long-term BTK data, BCL2 inhibition, and being a global company

  • Dec 8, 2024
  • 1 min read

Updated: Dec 9, 2024

He describes the different profile of degraders vs small molecules, and highlights BeiGene's programs in BTK, EGFR, IRAK4, and others. Plus ASH data for Brukinsa and a BCL2, and how BeiGene's investments in global scale are bearing fruition.



Join the BiotechTV mailing list

Thanks for subscribing!

Follow BiotechTV

  • Twitter
  • LinkedIn
  • Facebook
  • TikTok
  • Instagram

Also look for unique social pages for BiotechTV U.

Sponsor Spotlight

10x_Genomics_logo.svg.png

10x Genomics delivers powerful, reliable tools that fuel scientific discoveries and drive exponential progress to master biology to advance human health. Cited in more than 10,000 research papers, our innovative single cell, spatial, and in situ technologies enable discoveries across oncology, immunology, neuroscience, and more.

 

Our talented, dedicated science professionals have a distinguished record of creating innovative instruments, reagents, and software that analyze biological systems at a resolution that matches the complexity of biology.

bottom of page